Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 87

1.

Altered microRNA expression in B lymphocytes in multiple sclerosis: towards a better understanding of treatment effects.

Sievers C, Meira M, Hoffmann F, Fontoura P, Kappos L, Lindberg RL.

Clin Immunol. 2012 Jul;144(1):70-9. doi: 10.1016/j.clim.2012.04.002. Epub 2012 May 2.

PMID:
22659298
[PubMed - indexed for MEDLINE]
2.

Altered expression of miR-17-5p in CD4+ lymphocytes of relapsing-remitting multiple sclerosis patients.

Lindberg RL, Hoffmann F, Mehling M, Kuhle J, Kappos L.

Eur J Immunol. 2010 Mar;40(3):888-98. doi: 10.1002/eji.200940032.

PMID:
20148420
[PubMed - indexed for MEDLINE]
3.

Unraveling natalizumab effects on deregulated miR-17 expression in CD4+ T cells of patients with relapsing-remitting multiple sclerosis.

Meira M, Sievers C, Hoffmann F, Rasenack M, Kuhle J, Derfuss T, Kappos L, Lindberg RL.

J Immunol Res. 2014;2014:897249. doi: 10.1155/2014/897249. Epub 2014 May 12.

PMID:
24901013
[PubMed - indexed for MEDLINE]
Free PMC Article
4.

Glatiramer acetate treatment normalizes deregulated microRNA expression in relapsing remitting multiple sclerosis.

Waschbisch A, Atiya M, Linker RA, Potapov S, Schwab S, Derfuss T.

PLoS One. 2011;6(9):e24604. doi: 10.1371/journal.pone.0024604. Epub 2011 Sep 16.

PMID:
21949733
[PubMed - indexed for MEDLINE]
Free PMC Article
5.

Multiple sclerosis: microRNA expression profiles accurately differentiate patients with relapsing-remitting disease from healthy controls.

Keller A, Leidinger P, Lange J, Borries A, Schroers H, Scheffler M, Lenhof HP, Ruprecht K, Meese E.

PLoS One. 2009 Oct 13;4(10):e7440. doi: 10.1371/journal.pone.0007440.

PMID:
19823682
[PubMed - indexed for MEDLINE]
Free PMC Article
6.

Expression and genetic analysis of miRNAs involved in CD4+ cell activation in patients with multiple sclerosis.

Fenoglio C, Cantoni C, De Riz M, Ridolfi E, Cortini F, Serpente M, Villa C, Comi C, Monaco F, Mellesi L, Valzelli S, Bresolin N, Galimberti D, Scarpini E.

Neurosci Lett. 2011 Oct 17;504(1):9-12. doi: 10.1016/j.neulet.2011.08.021. Epub 2011 Aug 19.

PMID:
21875645
[PubMed - indexed for MEDLINE]
7.

miR-326 and miR-26a, two potential markers for diagnosis of relapse and remission phases in patient with relapsing-remitting multiple sclerosis.

Honardoost MA, Kiani-Esfahani A, Ghaedi K, Etemadifar M, Salehi M.

Gene. 2014 Jul 10;544(2):128-33. doi: 10.1016/j.gene.2014.04.069. Epub 2014 Apr 30.

PMID:
24792898
[PubMed - indexed for MEDLINE]
8.

Differential microRNA expression in blood in multiple sclerosis.

Søndergaard HB, Hesse D, Krakauer M, Sørensen PS, Sellebjerg F.

Mult Scler. 2013 Dec;19(14):1849-57. doi: 10.1177/1352458513490542. Epub 2013 Jun 17.

PMID:
23773985
[PubMed - indexed for MEDLINE]
9.

CD80 (B7-1) and CD86 (B7-2) expression in multiple sclerosis patients: clinical subtype specific variation in peripheral monocytes and B cells and lack of modulation by high dose methylprednisolone.

Boylan MT, Crockard AD, McDonnell GV, Armstrong MA, Hawkins SA.

J Neurol Sci. 1999 Aug 15;167(2):79-89.

PMID:
10521545
[PubMed - indexed for MEDLINE]
10.

MicroRNA expression changes during interferon-beta treatment in the peripheral blood of multiple sclerosis patients.

Hecker M, Thamilarasan M, Koczan D, Schröder I, Flechtner K, Freiesleben S, Füllen G, Thiesen HJ, Zettl UK.

Int J Mol Sci. 2013 Aug 5;14(8):16087-110. doi: 10.3390/ijms140816087.

PMID:
23921681
[PubMed - indexed for MEDLINE]
Free PMC Article
11.

Disappearance of cerebrospinal fluid oligoclonal bands after natalizumab treatment of multiple sclerosis patients.

von Glehn F, Farias AS, de Oliveira AC, Damasceno A, Longhini AL, Oliveira EC, Damasceno BP, Santos LM, Brandão CO.

Mult Scler. 2012 Jul;18(7):1038-41. doi: 10.1177/1352458511428465. Epub 2011 Oct 31.

PMID:
22041091
[PubMed - indexed for MEDLINE]
12.

Lymphocyte subsets show different response patterns to in vivo bound natalizumab--a flow cytometric study on patients with multiple sclerosis.

Harrer A, Pilz G, Einhaeupl M, Oppermann K, Hitzl W, Wipfler P, Sellner J, Golaszewski S, Afazel S, Haschke-Becher E, Trinka E, Kraus J.

PLoS One. 2012;7(2):e31784. doi: 10.1371/journal.pone.0031784. Epub 2012 Feb 20.

PMID:
22363732
[PubMed - indexed for MEDLINE]
Free PMC Article
13.

MiR-126: a novel route for natalizumab action?

Meira M, Sievers C, Hoffmann F, Derfuss T, Kuhle J, Kappos L, Lindberg RL.

Mult Scler. 2014 Sep;20(10):1363-70. doi: 10.1177/1352458514524998. Epub 2014 Mar 5.

PMID:
24598267
[PubMed - in process]
14.

Natalizumab disproportionately increases circulating pre-B and B cells in multiple sclerosis.

Krumbholz M, Meinl I, Kümpfel T, Hohlfeld R, Meinl E.

Neurology. 2008 Oct 21;71(17):1350-4. doi: 10.1212/01.wnl.0000327671.91357.96.

PMID:
18936427
[PubMed - indexed for MEDLINE]
15.

Natalizumab for relapsing-remitting multiple sclerosis.

Horga A, Tintoré M.

Neurologia. 2011 Jul-Aug;26(6):357-68. doi: 10.1016/j.nrl.2010.10.004. Epub 2010 Dec 28. Review. English, Spanish.

PMID:
21193250
[PubMed - indexed for MEDLINE]
Free Article
16.

Regulated microRNAs in the CSF of patients with multiple sclerosis: a case-control study.

Haghikia A, Haghikia A, Hellwig K, Baraniskin A, Holzmann A, Décard BF, Thum T, Gold R.

Neurology. 2012 Nov 27;79(22):2166-70. doi: 10.1212/WNL.0b013e3182759621. Epub 2012 Oct 17.

PMID:
23077021
[PubMed - indexed for MEDLINE]
17.

miR-15a and 16-1 are downregulated in CD4+ T cells of multiple sclerosis relapsing patients.

Lorenzi JC, Brum DG, Zanette DL, de Paula Alves Souza A, Barbuzano FG, Dos Santos AC, Barreira AA, da Silva WA.

Int J Neurosci. 2012 Aug;122(8):466-71. doi: 10.3109/00207454.2012.678444. Epub 2012 May 1.

PMID:
22463747
[PubMed - indexed for MEDLINE]
18.

Treatment of multiple sclerosis with anti-CD20 antibodies.

Barun B, Bar-Or A.

Clin Immunol. 2012 Jan;142(1):31-7. doi: 10.1016/j.clim.2011.04.005. Epub 2011 Apr 15. Review.

PMID:
21555250
[PubMed - indexed for MEDLINE]
19.

Occurrence of antibodies against natalizumab in relapsing multiple sclerosis patients treated with natalizumab.

Sørensen PS, Jensen PE, Haghikia A, Lundkvist M, Vedeler C, Sellebjerg F, Koch-Henriksen N, Fogdell-Hahn A, Myhr KM, Hillert J, Gold R.

Mult Scler. 2011 Sep;17(9):1074-8. doi: 10.1177/1352458511404271. Epub 2011 Apr 20.

PMID:
21511692
[PubMed - indexed for MEDLINE]
20.

CD49d expression as a promising biomarker to monitor natalizumab efficacy.

Defer G, Mariotte D, Derache N, Toutirais O, Legros H, Cauquelin B, Le Mauff B.

J Neurol Sci. 2012 Mar 15;314(1-2):138-42. doi: 10.1016/j.jns.2011.10.005. Epub 2011 Nov 1.

PMID:
22050952
[PubMed - indexed for MEDLINE]
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk